| Literature DB >> 30108615 |
Rui-Qi Zhuge1, Xiao-Pei Hou1, Xi-Ling Qi1, Yong-Jian Wu1, Ming-Zi Zhang2.
Abstract
OBJECTIVE: To summarize clinical characteristics and treatment strategy of Chinese elderly mitral regurgitation (MR) inpatients under the current guidelines, and to identify factors related to treatment options in them.Entities:
Keywords: Clinical features; Elderly patients; Mitral regurgitation; Treatment
Year: 2018 PMID: 30108615 PMCID: PMC6087515 DOI: 10.11909/j.issn.1671-5411.2018.06.005
Source DB: PubMed Journal: J Geriatr Cardiol ISSN: 1671-5411 Impact factor: 3.327
Baseline characteristics and echocardiographic parameters of elderly group and control group.
| Items | The elderly ( | Control ( | ||
| Age, yrs | 66.98 ± 5.94 | 46.04 ± 10.05 | < 0.001 | |
| Male | 397 (58.38%) | 630 (59.38%) | 0.680 | |
| Hypertension | 309 (45.44%) | 267 (25.16%) | < 0.001 | |
| Diabetes | 133 (19.56%) | 90 (8.48%) | < 0.001 | |
| Hyperlipidemia | 240 (35.29%) | 207 (19.51%) | < 0.001 | |
| Smoking | 176 (25.88%) | 304 (28.65%) | 0.178 | |
| Coronary heart disease | 227 (33.38%) | 171 (16.12) | < 0.001 | |
| NYHA | 0.155 | |||
| I | 52 (7.65%) | 96 (0.05%) | ||
| II | 184 (27.06%) | 330 (31.10%) | ||
| III | 359 (52.79%) | 512 (48.26%) | ||
| IV | 85 (12.50%) | 123 (11.59%) | ||
| Euroscore-II index | 5.54 ± 2.42 | 3.15 ± 1.66 | < 0.001 | |
| Euroscore-II risk | < 0.001 | |||
| Low | 26 (3.82%) | 421 (39.68%) | ||
| Moderate | 375 (55.15%) | 552 (52.02%) | ||
| High | 279 (41.03%) | 88 (8.29%) | ||
| LVEF | 55.31% ± 14.48% | 57.61% ± 15.03% | 0.002 | |
| LVEF stratification | < 0.001 | |||
| > 60% | 287 (42.21%) | 560 (52.78%) | < 0.001 | |
| 30%–60% | 335 (49.26%) | 402 (37.89%) | ||
| < 30% | 58 (8.53%) | 99 (9.33%) | ||
| Left atrium diameter, mm | 47.38 ± 10.44 | 48.22 ± 11.13 | 0.109 | |
| Left ventricular end-diastolic dimension, mm | 57.33 ± 10.19 | 57.72 ± 12.37 | < 0.001 | |
| Mitral calcification | 144 (21.18%) | 197 (18.57%) | 0.181 | |
| Multiple valve disease | 242 (35.59%) | 433 (40.81%) | ||
| MR grade | 0.091 | |||
| Severe | 275 (40.44%) | 484 (45.62%) | ||
| Moderate | 405 (59.56%) | 577 (54.38%) | ||
| MR etiology | < 0.001 | |||
| *Primary | ||||
| Degenerative | 280 (41.18%) | 358 (33.74%) | < 0.001 | |
| Rheumatic | 138 (20.29%) | 217 (20.45%) | < 0.001 | |
| Congenital | 23 (3.38%) | 112 (10.56%) | ||
| Inflammatory | 11 (1.62%) | 48 (4.52%) | ||
| #Secondary | ||||
| Ischemic | 124 (18.24%) | 92 (8.67%) | ||
| Cardiomyopathy | 92 (13.53%) | 205 (19.32%) | ||
| Other or unknown | 12 (1.76%) | 29 (2.73%) | ||
| Treatment option | < 0.001 | |||
| Medicine | 308 (45.29%) | 383 (36.10%) | < 0.001 | |
| Valve surgery | 372 (54.71%) | 678 (63.91%) | < 0.001 | |
| Surgery approaches | 0.293 | |||
| Valve repair | 139 (37.37%) | 286 (42.18%) | ||
| Valve replacement | 233 (62.63%) | 392 (57.82%) | ||
| Prosthetic valve | < 0.001 | |||
| Bioprosthetic | 126 (54.08%) | 74 (18.88%) | ||
| Mechanical | 107 (45.92%) | 318 (81.12%) | ||
| Death during hospitalization | 6 (0.88%) | 4 (0.38%) | 0.173 | |
Data presented as mean ± SD or n (%). *In primary MR, the pathology of ≥ 1 of the components of the valve (leaflets, chordae tendineae, papillary muscles, annulus) causes valve incompetence with systolic regurgitation; #In secondary MR, the mitral valve is usually normal. The abnormal and dilated left ventricle caused by cardiovascular disease or related MI (ischemic MR) leads to papillary muscle displacement, which in turn results in leaflet tethering with associated annular dilation. LVEF: left ventricular ejection fraction; MI: myocardial infarction; MR: mitral regurgitation.
Figure 1.The association between age stratification and treatment option in MR inpatients.
MR: mitral regurgitation.
Clinical characteristics and surgery status of older patients.
| 70–80 yrs, | > 80 yrs, | ||
| Mean age, yrs | 73.41 ± 2.58 | 83.27 ± 2.83 | < 0.001 |
| Male | 97 (61.00%) | 20 (66.67%) | 0.213 |
| MR grade | 0.313 | ||
| Severe | 34 (21.38%) | 4 (13.33%) | |
| Moderate | 125 (78.62%) | 26 (86.67%) | |
| MR etiology | |||
| Degenerative | 66 (41.51%) | 15 (50.00%) | 0.389 |
| Coronary heart disease | 65 (40.88%) | 8 (26.67%) | 0.142 |
| Euroscore-II index | 7.10 ± 2.51 | 9.10 ± 2.66 | < 0.001 |
| LVEF | 54.40% ± 15.26% | 49.21% ± 15.49% | 0.09 |
| Treatment option | 0.003 | ||
| Medicine | 99 (62.26%) | 27 (90.00%) | |
| Valve surgery | 60 (37.74%) | 3 (10.00%) | |
| Surgery approaches | 0.967 | ||
| Valve repair | 20 (33.33%) | 1 (33.33%) | |
| Valve replacement | 40 (66.67%) | 2 (66.67%) |
Data presented as mean ± SD or n (%). LVEF: left ventricular ejection fraction; MR: mitral regurgitation.
Characteristics and treatment of MR patients with primary indications for cardiac revascularization in both groups.
| The elderly ( | Control ( | ||
| Mean age, yrs | 67.53 ± 5.48 | 50.36 ± 8.65 | < 0.001 |
| Male | 150 (66.08%) | 123 (71.93%) | 0.213 |
| Coronary angiography | < 0.001 | ||
| Single vessel disease | 63 (9.26%) | 61 (5.75%) | |
| Double vessel disease | 44 (6.47%) | 44 (4.15%) | |
| Three vessel disease | 120 (17.65%) | 66 (6.22%) | |
| Treatment option | 0.283 | ||
| No surgery treatment | 93 (40.97%) | 61 (35.67%) | |
| Surgery treatment | 134 (59.03%) | 110 (64.33%) | |
| CABG alone | 27 (20.15%) | 26 (23.64%) | 0.336 |
| MV alone | 10 (7.46%) | 9 (8.18%) | 0.691 |
| MV + CABG | 97 (72.39%) | 75 (68.18%) | 0.822 |
Data presented as mean ± SD or n (%). CABG: coronary artery bypass grafting; MR: mitral regurgitation; MV: mitral valve.
Baseline clinical characteristics and echocardiographic parameters of valve surgery sub-group and medicine sub-group of elderly patients.
| Items | Valve surgery ( | Medicine ( | |
| Age, yrs | 65.33 ± 4.54 | 68.97 ± 6.78 | < 0.001 |
| Male | 217 (58.33%) | 180 (58.44%) | 0.977 |
| BMI | 23.57 ± 3.43 | 23.33 ± 3.68 | 0.367 |
| Hospital stay | 16.62 ± 8.72 | 10.64 ± 8.84 | 0.338 |
| Hypertension | 138 (37.10%) | 171 (55.52%) | < 0.001 |
| Diabetes | 47 (12.63%) | 86 (27.92%) | < 0.001 |
| Hyperlipidemia | 91 (24.46%) | 149 (48.38%) | < 0.001 |
| Coronary heart disease | 107 (28.76%) | 120 (38.96%) | < 0.001 |
| Recent MI | 4 (1.08%) | 28 (9.09%) | < 0.001 |
| Heart surgery history | 5 (1.34%) | 18 (5.84%) | 0.001 |
| NYHA | 0.01 | ||
| I | 15 (4.03%) | 37 (12.01%) | |
| II-IV | 357 (95.97%) | 271 (87.99%) | |
| Euroscore-II index | 5.04 ± 1.73 | 6.14 ± 2.95 | < 0.001 |
| Euroscore-II risk | < 0.001 | ||
| Low or moderate | 254 (68.28%) | 147 (47.73%) | |
| High | 118 (31.72%) | 161 (52.27%) | |
| LVEF | 61.54 ± 9.19 | 47.78 ± 16.06 | < 0.001 |
| LVEF stratification | < 0.001 | ||
| > 60% | 213 (57.26%) | 74 (24.03%) | |
| 30%–60% | 158 (42.47%) | 177 (57.47%) | |
| < 30% | 1 (0.27%) | 57 (18.51%) | |
| MR grade | < 0.001 | ||
| Severe | 200 (53.76%) | 75 (24.35%) | |
| Moderate | 172 (46.24%) | 233 (75.65%) | |
| Left atrium diameter, mm | 49.38 ± 11.02 | 44.98 ± 9.16 | 0.001 |
| Left ventricular end diastolic dimension, mm | 55.77 ± 8.81 | 59.21 ± 11.37 | < 0.001 |
| Mitral calcification | 112 (30.11%) | 32 (10.39%) | < 0.001 |
| Mitral prolapse | 176 (47.31%) | 25 (8.12%) | < 0.001 |
| Pulmonary hypertension | 102 (27.42%) | 85 (27.60%) | 0.959 |
| Multiple valve disease | 253 (68.01%) | 185 (60.06%) | 0.031 |
| MR etiology | < 0.001 | ||
| Primary | 323 (86.83%) | 129 (41.88%) | |
| Secondary | 49 (12.17%) | 179 (58.12%) | |
| Death during hospitalization | 2 (0.54%) | 4 (1.30%) | 0.291 |
Data presented as mean ± SD or n (%). BMI: body mass index; LVEF: left ventricular ejection fraction; MI: myocardial infarction; MR: mitral regurgitation.
Factors associated with the treatment option of surgery (multivariable analysis).
| Items | B | S.E. | Wald | df | OR | 95%CI lower | 95%CI upper | |
| Severe regurgitation | 4.128 | 1.239 | 11.098 | 1 | 0.001 | 62.067 | 5.471 | 704.185 |
| Normal LVEF | 0.086 | 0.008 | 119.020 | 1 | < 0.001 | 1.089 | 1.073 | 1.106 |
| Age increase (per 1year increase) | –0.130 | 0.018 | 52.719 | 1 | < 0.001 | 0.879 | 0.848 | 0.910 |
| Diabetes | –0.883 | 0.440 | 4.029 | 1 | 0.045 | .414 | 0.175 | 0.979 |
| EuroScore-II high risk | –3.169 | .720 | 19.349 | 1 | < 0.001 | .042 | .010 | .173 |
LVEF: left ventricular ejection fraction.
Figure 2.The association between LVEF stratification and treatment option in elderly MR inpatients.
LVEF: left ventricular ejection fraction; MR: mitral regurgitation.